CD274 and hepatocellular carcinoma: Blocking PD-L1/PD-1 interactions in vitro selectively interfered with inhibitory Treg–T-effector cell interactions in patients with HCC and resulted in improved antitumoral activity against checkpoint-inhibitor-negative tumor cells, as well [47].